X

News

ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy

Rockville, MD, USA, November 17, 2020

ReveraGen, Inc., a privately held company developing vamorolone (VBP15) as a potential safer alternative for corticosteroid treatment in Duchenne muscular dystrophy and other disorders, today announced an award of a $3.3 million grant

More >

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy

Pratteln, Switzerland, and Rockville, MD, USA, September 22, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data 

More >

Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids

Pratteln, Switzerland, and Rockville, MD, USA, September 14, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of vamorolone compared to standard corticosteroids 

More >

Santhera Announces Full Enrollment of ReveraGen’s Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, and Rockville, MD, USA, September 11, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD).  

More >

Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications

Pratteln, Switzerland, and Rockville, MD, USA, September 2, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that it has signed agreements with Idorsia (SIX: IDIA) and ReveraGen BioPharma Inc., making Santhera a direct license holder of vamorolone.  

More >

Jesse’s Journey grants $1M toward the launch of a clinical trial for Duchenne muscular dystrophy in Canada

Rockville MD, 11 June 2020

Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in

More >

ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys

Rockville MD, 2 June 2020

Vamorolone is a first-in-class daily oral drug being developed to improve muscle function in Duchenne muscular dystrophy. Vamorolone has multiple mechanisms of action shown by published pre-clinical studies, including potent anti-inflammatory 

More >